AbCellera Biologics Inc.

Good afternoon, and welcome to Abceleras Q3 2024 Business Update Conference Call. My name is Tamia, and I will facilitate the audio portion of today's interactive broadcast. If you would like to ask a question, please press star 1 on your telephone keypad. If you require assistance at any time during the call, please press star 0 to access the help hotline. At this time, I would now like to turn the call over to Trent Steinmark, Abceleras Chief Legal and Compliance Officer. You may proceed.

Thank you. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for joining us for Abcelera's 2024 Third Quarter Earnings Call. I'm Trinh Steimart, Abcelera's Chief Legal and Compliance Officer. Joining me on today's call are Dr. Carl Hansen, Abcelera's President and CEO, and Andrew Booth, Abcelera's Chief Financial Officer. During this call, we anticipate making projections and forward-looking statements based on our current expectations and pursuance of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially due to several factors as set forth in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. A bestseller does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Our presentation today includes being our earnings press release issued earlier today and our SEC filings are available on our investor relations website. The information we provide about our pipeline is for the benefit of the investment community and is not intended to be promotional. As we transition to our prepared remarks, please note that all dollars referred to during the call are in U.S. dollars. After our prepared remarks, we will open the lines for questions and answers. Now, I'll turn the call over to Carl Hansen.

Thanks, Trinh, and thank you everyone for joining us today. Given that there were a few new disclosures this quarter, I'll use today's prepared remarks to give a brief update on Abcelera's position and our progress. It was a year ago that we committed to building an internal pipeline and transitioning from a platform company to a clinical stage biotech. Over the past 12 months, we've reorganized our teams and reallocated our investments, focusing on advancing our internal programs and completing the build of our platform capabilities. The first two programs in our pipeline, ABCL635 and ABCL575, are on track for CTA filings in Q2 of next year. Behind them, we are prosecuting a broad portfolio of discovery stage programs. This includes wholly owned programs against multi-pass transmembrane protein targets, T cell engagers, and a smaller number of 50-50 co-development programs on novel targets and to greater antibody conjugates. We are pleased with the breadth and the quality of this portfolio, and we are confident that it will mature into a pipeline of differentiated clinical assets. At the same time, we are now in the final stages of building our capabilities and facilities. Notably, this quarter, we completed the move-in to our new headquarters in Vancouver, finalizing a project that began back in 2020. We also continue to make steady progress on our GMP manufacturing facility, which remains on track and will come online in 2025. Additionally, over the past year, we have built our translational and development teams and are well prepared for our first two clinical trials starting next year. We anticipate further investments in this team as our pipeline continues to advance and to grow. Turning to partnering, as mentioned on the last call, this quarter we expanded our partnership with Eli Lilly. Consistent with our focus on pipeline development, our partnering priority moving forward is to build on co-development collaborations where we have co-ownership of resulting assets. In addition, we will continue to look to engage with existing and new partners on our TCE platform. And in relation to this, we will be presenting updated data on our TCE platform later this week at CITSE. I'd like to end by thanking our leadership and teams for their work in successfully navigating what has been a year full of change and challenge. We are clearly on track in our transition to a clinical stage company. Over the coming years, With focus and execution, I am confident that this path will deliver maximum value to patients and to shareholders. And with that, I will hand it over to Andrew to discuss our financials. Andrew?